On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their February 2024 meeting. Actions in this consultation include:

  • Riluzole 50mg orodispersible tablets added as AMBER
  • Diclofenac 50mg tablets made 3rd line choice, after ibuprofen and naproxen
  • Sebeliplase alfa added as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 28th March 2024. To take part, visit the consultations page.